Hojabr Alimi
CIK 1367080 · Chief Executive Officer · last filed 2012-12-11
Hojabr Alimi is a Chief Executive Officer who has filed 12 SEC Form 4 insider transactions across 1 company since 2007. The most recent filing shows the insider bought $3.4K of OCLS on Dec 11, 2012. Across all open-market trades the lifetime net is −$824.4K, making them a net seller over the disclosed history. 14 SEC filings were submitted jointly with Oculus Innovative Sciences, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OCLS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PETALUMA, CA 94954
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Chief Executive Officer | 147,293 | — | — | -$824.4K | 12 | 2012-12-11 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-12-11 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Buy (P) | +5,300 | $3.4K | EDGAR |
| 2012-12-10 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Buy (P) | +5,500 | $3.5K | EDGAR |
| 2012-12-07 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Buy (P) | +9,000 | $5.7K | EDGAR |
| 2010-06-09 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-03-11 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Mixed | — | -$30.8K | EDGAR |
| 2009-08-12 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Mixed | — | -$610.0K | EDGAR |
| 2009-03-12 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-03-09 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Sell (S) | −13,200 | -$13.9K | EDGAR |
| 2009-03-05 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Mixed | −31,800 | -$37.1K | EDGAR |
| 2008-03-13 | Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Sell (S) | −15,000 | -$80.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.